<DOC>
	<DOCNO>NCT00279708</DOCNO>
	<brief_summary>This study determine atorvastatin ( Lipitor ) help patient pulmonary ( lung ) sarcoidosis replace reduce need patient take steroid , prednisone . Sarcoidosis inflammatory disease affect nearly part body . Pulmonary sarcoidosis may resolve may progress irreversible lung damage , disability , death . Many sarcoidosis patient treat prednisone , drug effective patient , cause serious side effect , high blood pressure , sugar diabetes , eye cataract , bone thinning . Patients stage II III pulmonary sarcoidosis 18 70 year age require prednisone may eligible study . Candidates screen test procedure describe . Participants randomly assign one two treatment group : one group take atorvastatin ; take placebo ( look-alike pill active ingredient fight sarcoidosis ) . Both group take pill mouth day 12 month . When treatment begin , participant begin prednisone dosage taper ( reduce ) . The taper do 8 week dose reduce 90 percent . Patients evaluate periodically determine two group differ long remain reduced dose prednisone without symptom recur , require increase prednisone dose . A full battery test do initial screen visit 26- 52-week follow-up visit , require hospitalization 3-5 day . Additional interim outpatient assessment do 6 , 12 , 18 36 week . The full battery test initial screen 26- 52-week visit include follow : - Medical history , physical examination , blood urine test , assessment disease severity activity . - Questionnaires . - Chest x-ray ( CXR ) compute tomography ( CT ) scan . - Abdominal ultrasound . - Six-minute walk test ( 6MWT ) - Exercise test blood gas - Pulmonary function test ( PFT ) - Maximum incremental ventilatory performance test ( MIVP ) - Exhaled nitric oxide carbon monoxide ( Exhaled NO CO ) - Bronchoscopy lavage Interim test 6 , 12 , 18 36 week include PFT , MIVP , Exhaled NO CO , CXR , questionnaire , blood test , 6MWT . Six month complete study , participant fill questionnaire .</brief_summary>
	<brief_title>Atorvastatin Treat Pulmonary Sarcoidosis</brief_title>
	<detailed_description>Background Sarcoidosis multi-system granulomatous inflammatory disease . Pulmonary involvement common . Patients typically experience fatigue , weakness dyspnea . Respiratory muscle weakness , may secondary granulomatous inflammation , associate dyspnea decrease quality life ( QOL ) . The disease remit spontaneously become chronic , exacerbation remission . In patient , progress pulmonary fibrosis death . Granulomatous inflammation characterize primarily accumulation monocyte , macrophage activate T-lymphocytes , increase production key inflammatory mediator , TNF-alpha , INF-gamma , IL-2 IL-12 , characteristic Th1-polarized response ( T-helper lymphocyte-1 response ) . Corticosteroids current mainstay treatment , long-term benefit certain . Because steroid often produce undesirable side effect , investigation identify alternative therapy warrant . There sufficient evidence test proof concept pathway target statin therapeutic effect sarcoidosis , since , pre-clinical study , statin blunt Th1-mediated inflammatory response . Aims The study involve double-blind placebo-controlled , randomized trial aim determine atorvastatin administration result less steroid use longer steroid-free interval patient pulmonary sarcoidosis require prednisone treatment . Methods Patients , 18-70 year old , stage II III pulmonary sarcoidosis , diagnose compatible clinical history support lung , lymph node , tissue biopsy , enrol study , require prednisone therapy . The patient randomly assign two group ; prednisone taper , one group receive placebo , atorvastatin . The two study drug administer twelve month , time patient periodically evaluate clinical status prednisone requirement . Pill count patient diary use determine amount steroid use study period . Patients pulmonary fibrosis great 50 percent total lung volume severe co-morbidities exclude trial . The primary endpoint duration steroid-sparing period . Secondary clinical physiological endpoint intend analyze possible anti-inflammatory beneficial effect drug . Since gold standard outcome measure sarcoidosis , four category secondary endpoint use characterize effect therapeutic agent clinical course disease : imaging ( high resolution chest CT ) ; quality life assessment ( SF-36 , SGRQ ) , anti-inflammatory effect ( biomarkers relapse rate ) , functional effect ( CPET , PFTs ) . Finally , study utility exhale nitric oxide carbon monoxide monitor disease activity .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients eligible trial 1870 year old radiographic stage II III pulmonary sarcoidosis , prednisone , methotrexate , azathioprine pulmonary sarcoidosis steroidrequiring . Patients extrapulmonary sarcoidosis ( except cardiac neurosarcoidosis ) may eligible long active pulmonary ( stage II III ) sarcoidosis . SteroidRequiring History : A steroidrequiring patient one previously stable ultimately experience ( ) increase symptom associate radiographic deterioration , and/or , ( b ) meet criterion relapse and/or functional deterioration . In addition , patient prescribe prednisone sarcoidosis , selfdiscontinued ( yet still clinical symptomatic disease and/or evidence pulmonary functional deterioration ) consider steroidrequiring . This latter group steroidrequiring patient eligible enrollment willing resume take late stabilize dose prednisone least four week prior study entry . If dose determine , 40 mg use . Therefore , history symptomatic clinical deterioration lead therapy initiation , history decline associate attempt decrease therapy establish . Medical record review discussion prescribe physician use establish history . Radiographic Stages Pulmonary Sarcoidosis : STAGE &lt; TAB &gt; DESCRIPTION 0 &lt; TAB &gt; Normal Chest Radiograph I &lt; TAB &gt; Bilateral Hilar Lymphadenopathy II &lt; TAB &gt; Pulmonary Infiltration Bilateral Hilar Lymphadenopathy III &lt; TAB &gt; Pulmonary Infiltration alone Steroidrequiring refers one three situation : Patients meet relapse criterion functional deterioration . Functional deterioration criterion warrant prednisone therapy include : If VC fell 75 % best record value patient treatment If VC fell great 50 % predict value IF DLCO fell less 60 % best record value prior treatment Patients previously prescribe systemic steroid , alternative agent methotrexate azathioprine , primarily pulmonary sarcoidosis . Alternative agent must first change roughly equivalent antiinflammatory dose prednisone patient stable dose least four week prior randomization . Patients substantial respiratory symptom ( distress cough dyspnea , interfere daily activity would warrant therapy per standard practice US . Extra Pulmonary Sarcoidosis : Patients extra pulmonary sarcoidosis ( except neurosarcoidosis cardiac sarcoidosis ) may eligible long active pulmonary ( stage II III ) sarcoidosis . All patient refer NIH ophthalmologist . Steroid therapy may modify base upon recommendation consultant , well per lapse criterion describe . EXCLUSION CRITERIA : Moderate severe pulmonary fibrosis ( stage IV sarcoidosis great 50 % fibrosis ) Lung Disease asthma , COPD , ILD ( sarcoidrelated ) History significant beryllium asbestos exposure Pregnancy ; Active lactation/ childbearing age female without appropriate birth control method HIV disease Hepatitis C Active Hepatitis B Other intervention protocol Immunosuppressive therapy ( systemic inhale ) corticosteroid methotrexate Significant cardiac disease ( NYSHA class great III ) , serious coronary disease ( unstable angina ) Use statin within 12 week enrollment Allergies intolerance statins Liver disease ( transaminases great 1.5X upper limit normal ) cirrhosis Bleeding diathesis correctable Inability perform CPET ( cycle ergometer ) PFT maneuver Inability understand risk trial inability complete questionnaire Malignancy require chemotherapy radiation therapy ; except certain type skin cancer excise spread . Myopathy , diagnose via muscle biopsy ( sarcoidrelated myopathy ) ; CPK grater 1.5 upper limit normal Surgical Risk Category [ American Society Anesthesiologists ( ASA ) class IV Ingestion grapefruit juice certain herbal preparation ( see ) , medication potent inhibitor inducer CYP3A4 system ( see section 12.4 precaution ) Alcohol abuse ( great 4 drinks/day ) Bleeding brain part eye ( retina ) ( within past year prior enrollment ) Uncontrolled Hypertension ( SBP great 185 DBP great 100 two visit assessment ) Uncontrolled Diabetes Mellitus ( Serum glucose level two test per day great 250 mg/dl erratic blood sugar level , note least 2 assessment ; and/or HgbA1C great 2x upper limit normal ) . Neurosarcoidosis Sarcoid Uveitis ( Posterior Uveitis ) Uveitis manage topical steroid alone , determined ophthalmologist ( Clinically apparent ) Cardiac Sarcoidosis Active Smoker ( Smoked within past 2 month prior randomization ) Sickle cell disease ( SS , SC , sickle cellbeta thalassemia ) Aseptic necrosis hip joint Patients take follow preparation allow participate study unless agree discontinue usage least two week prior randomization duration study period : grapefruit juice herbal remedy may lead severe liver injury and/or muscle injury take atorvastatin , include : Skullcap , chaparral , Germander , Jin Bu Huan , Valerian , Comfrey , Eucalyptus . Since product St. John Wort , oat bran , pectin reduce effectiveness atorvastatin , similar agent , also discontinue least two week randomization duration study period . Subjects inactive hepatitis B require antiviral prophylaxis agent lamivudine , prednisone therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Granulomatous Inflammation</keyword>
	<keyword>Steroid-Sparing</keyword>
	<keyword>Pulmonary Function</keyword>
	<keyword>Sarcoidosis , Pulmonary</keyword>
	<keyword>Statins ( Atorvastatin )</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Disease Activity</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Pulmonary Sarcoidosis</keyword>
	<keyword>Sarcoidosis</keyword>
</DOC>